The Notch Signaling Pathway Contributes to Angiogenesis and Tumor Immunity in Breast Cancer

References

• Sung H, Ferlay J, Siegel RL., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013;34(7):1420–1430.
   PubMed Web of Science ®Google Scholar
• Korkaya H, Wicha MSHER-2. Notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res. 2009;15(6):1845–1847.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Shen S, Zhou Y, et al. NOTCH1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells. Onco Targets Ther. 2016;9:6865–6871.
   PubMed Web of Science ®Google Scholar
• Giuli MV, Giuliani E, Screpanti I, Bellavia D, Checquolo S. Notch signaling activation as a hallmark for triple-negative breast cancer subtype. J Oncol. 2019;2019:8707053.
   PubMed Web of Science ®Google Scholar
• Yuan X, Zhang M, Wu H, et al. Expression of Notch1 correlates with breast cancer progression and prognosis. PLoS One. 2015;10(6):e0131689.
   PubMed Web of Science ®Google Scholar
• Ercan C, van Diest PJ, Vooijs M. Mammary development and breast cancer: the role of stem cells. Curr Mol Med. 2011;11(4):270–285.
   PubMed Web of Science ®Google Scholar
• Lee JH, Zhao XM, Yoon I, et al. Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. Cell Discov. 2016;2:16025.
   PubMed Web of Science ®Google Scholar
• Florena AM, Tripodo C, Guarnotta C, et al. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients. Pathobiology. 2007;74(6):317–322.
   PubMed Web of Science ®Google Scholar
• Alanazi IO, Shaik JP, Parine NR, et al. NOTCH single nucleotide polymorphisms in the predisposition of breast and colorectal cancers in Saudi patients. Pathol Oncol Res. 2021;27:616204. doi:10.3389/pore.2021.616204
   PubMed Web of Science ®Google Scholar
• Hirose H, Ishii H, Mimori K, et al. Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors. Oncol Rep. 2010;23(1):35–43.
   PubMed Web of Science ®Google Scholar
• Leontovich AA, Jalalirad M, Salisbury JL, et al. NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Res. 2018;20(1):105. doi:10.1186/s13058-018-1020-0
   PubMed Web of Science ®Google Scholar
• Mittal S, Subramanyam D, Dey D, Kumar RV, Rangarajan A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer. 2009;8(1):128. doi:10.1186/1476-4598-8-128
   PubMed Web of Science ®Google Scholar
• Wang J-W, Wei X-L, Dou X-W, Huang W-H, Du C-W, Zhang G-J. The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer. Oncol Lett. 2018;15(6):8749–8755. doi:10.3892/ol.2018.8442
   PubMed Web of Science ®Google Scholar
• Kim DC, Jin H, Lee JS, Son E, Lee GW, Kim HJ. P2Y(2)R has a significant correlation with Notch-4 in patients with breast cancer. Oncol Lett. 2020;20(1):647–654.
   PubMed Web of Science ®Google Scholar
• Pece S, Serresi M, Santolini E, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol. 2004;167(2):215–221.
   PubMed Web of Science ®Google Scholar
• Rennstam K, McMichael N, Berglund P, et al. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. Breast Cancer Res Treat. 2010;122(2):315–324.
   PubMed Web of Science ®Google Scholar
• Edwards A, Brennan K. Notch signalling in breast development and cancer. Front Cell Dev Biol. 2021;9:692173.
   PubMed Web of Science ®Google Scholar
• Kumar S, Nandi A, Singh S, et al. Dll1(+) quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nat Commun. 2021;12(1):432.
   PubMed Web of Science ®Google Scholar
• Yuan C, Chang K, Xu C, Li Q, Du Z. High expression of DLL3 is associated with a poor prognosis and immune infiltration in invasive breast cancer patients. Transl Oncol. 2021;14(7):101080.
   PubMed Web of Science ®Google Scholar
• Zohny SF, Zamzami MA, Al-Malki AL, Trabulsi NH. Highly Expressed DLL4 and JAG1: their Role in Incidence of Breast Cancer Metastasis. Arch Med Res. 2020;51(2):145–152.
   PubMed Web of Science ®Google Scholar
• Andrieu G, Tran AH, Strissel KJ, Denis GV. BRD4 regulates breast cancer dissemination through Jagged1/Notch1 signaling. Cancer Res. 2016;76(22):6555–6567.
   PubMed Web of Science ®Google Scholar
• Li CY, Miao KL, Chen Y, et al. Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200. Eur Rev Med Pharmacol Sci. 2018;22(18):6008–6014.
   PubMed Web of Science ®Google Scholar
• Shen Q, Reedijk M. Notch signaling and the breast cancer microenvironment. Adv Exp Med Biol. 2021;1287:183–200.
   PubMed Web of Science ®Google Scholar
• Glittenberg M, Pitsouli C, Garvey C, Delidakis C, Bray S. Role of conserved intracellular motifs in Serrate signalling, cis-inhibition and endocytosis. EMBO j. 2006;25(20):4697–4706.
   PubMed Web of Science ®Google Scholar
• Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216–233.
   PubMed Web of Science ®Google Scholar
• Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284(5415):770–776.
   PubMed Web of Science ®Google Scholar
• Weinmaster G. Notch signal transduction: a real rip and more. Curr Opin Genet Dev. 2000;10(4):363–369.
   PubMed Web of Science ®Google Scholar
• Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, et al. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology. 2010;139(6):2113–2123.
   PubMed Web of Science ®Google Scholar
• Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature. 1995;377(6547):355–358.
   PubMed Web of Science ®Google Scholar
• Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998;393(6683):382–386.
   PubMed Web of Science ®Google Scholar
• Petcherski AG, Kimble J. Mastermind is a putative activator for Notch. Curr Biol. 2000;10(13):R471–473.
   PubMed Web of Science ®Google Scholar
• Nam Y, Sliz P, Song L, Aster JC, Blacklow SC. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell. 2006;124(5):973–983.
   PubMed Web of Science ®Google Scholar
• Fortini ME, Artavanis-Tsakonas S. The suppressor of hairless protein participates in notch receptor signaling. Cell. 1994;79(2):273–282.
   PubMed Web of Science ®Google Scholar
• Struhl G, Adachi A. Nuclear access and action of notch in vivo. Cell. 1998;93(4):649–660.
   PubMed Web of Science ®Google Scholar
• Yu MM, Zhou QM. 3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition, migration and invasion in endometrial stromal cells by inhibiting the Notch signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(12):4009–4017.
   PubMed Web of Science ®Google Scholar
• Reedijk M. Notch signaling and breast cancer. Adv Exp Med Biol. 2012;727:241–257.
   PubMed Web of Science ®Google Scholar
• Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci. 2009;66(10):1631–1646.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11):1359–1370.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–364.
   PubMed Web of Science ®Google Scholar
• Lawson ND, Scheer N, Pham VN, et al. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development. 2001;128(19):3675–3683.
   PubMed Web of Science ®Google Scholar
• Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: who is talking to whom about what? Circ Res. 2007;100(11):1556–1568.
   PubMed Web of Science ®Google Scholar
• Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin MT, Liao JK. Essential role of endothelial Notch1 in angiogenesis. Circulation. 2005;111(14):1826–1832.
   PubMed Web of Science ®Google Scholar
• Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, Weinmaster G. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev. 2001;108(1–2):161–164.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Kume T. Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS One. 2008;3(6):e2401.
   PubMed Web of Science ®Google Scholar
• Surendran S, Suresh A. Arterialization and anomalous vein wall remodeling in varicose veins is associated with upregulated FoxC2-Dll4 pathway. Lab Invest. 2016;96(4):399–408.
   PubMed Web of Science ®Google Scholar
• Xia S, Menden HL, Korfhagen TR, Kume T, Sampath V. Endothelial immune activation programmes cell-fate decisions and angiogenesis by inducing angiogenesis regulator DLL4 through TLR4-ERK-FOXC2 signalling. J Physiol. 2018;596(8):1397–1417.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang W, Yang Q, Zhou S. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype. Histol Histopathol. 2012;27(4):475–484.
   PubMed Web of Science ®Google Scholar
• Liu HXJ, Zheng YY, et al. Influence of FOXC2 in angiogenesis of breast cancer MCF-7 cells by DLL4/Notch1 signal pathway. J Jilin Univ. 2014;40(3):488–492.
   Google Scholar
• Zhu Q, Li J, Wu Q, et al. Linc-OIP5 in the breast cancer cells regulates angiogenesis of human umbilical vein endothelial cells through YAP1/Notch/NRP1 signaling circuit at a tumor microenvironment. Biol Res. 2020;53(1):5.
   PubMed Web of Science ®Google Scholar
• Hultgren NW, Fang JS, Ziegler ME, et al. Slug regulates the Dll4-Notch-VEGFR2 axis to control endothelial cell activation and angiogenesis. Nat Commun. 2020;11(1):5400.
   PubMed Web of Science ®Google Scholar
• Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found Symp. 2007;283:106–120.
   PubMedGoogle Scholar
• Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006;107(3):931–939.
   PubMed Web of Science ®Google Scholar
• Erkasap N, Ozyurt R, Ozkurt M, et al. Role of Notch, IL-1 and leptin expression in colorectal cancer. Exp Ther Med. 2021;21(6):600.
   PubMed Web of Science ®Google Scholar
• Cao W, Zhao F, Zhao Y, Jing Z. Effect and correlation of VEGF and Notch1 in invasion and metastasis of breast cancer. J Basic Clin Oncol. 2012;25(6):480–483.
   Google Scholar
• Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005;65(19):8690–8697.
   PubMed Web of Science ®Google Scholar
• Oon CE, Bridges E, Sheldon H, et al. Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget. 2017;8(25):40115–40131.
   PubMedGoogle Scholar
• Pedrosa AR, Trindade A, Fernandes AC, et al. Endothelial Jagged1 antagonizes Dll4 regulation of endothelial branching and promotes vascular maturation downstream of Dll4/Notch1. Arterioscler Thromb Vasc Biol. 2015;35(5):1134–1146.
   PubMed Web of Science ®Google Scholar
• Mailhos C, Modlich U, Lewis J, Harris A, Delta4 I-HD. an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation. 2001;69(2–3):135–144.
   PubMed Web of Science ®Google Scholar
• Gale NW, Dominguez MG, Noguera I, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A. 2004;101(45):15949–15954.
   PubMed Web of Science ®Google Scholar
• Benedito R, Trindade A, Hirashima M, et al. Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev Biol. 2008;8:117.
   PubMed Web of Science ®Google Scholar
• Benedito R, Roca C, Sörensen I, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell. 2009;137(6):1124–1135.
   PubMed Web of Science ®Google Scholar
• Xue Y, Gao X, Lindsell CE, et al. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet. 1999;8(5):723–730.
   PubMed Web of Science ®Google Scholar
• Pitulescu ME, Schmidt I, Giaimo BD, et al. Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. Nat Cell Biol. 2017;19(8):915–927.
   PubMed Web of Science ®Google Scholar
• Zhou R, Wang S, Wen H, Wang M, Wu M. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models. Exp Cell Res. 2019;380(2):141–148.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhou R, Sun F, Li R, Wang M, Wu M. The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models. Cancer Lett. 2017;409:125–136.
   PubMed Web of Science ®Google Scholar
• High FA, Lu MM, Pear WS, Loomes KM, Kaestner KH, Epstein JA. Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc Natl Acad Sci U S A. 2008;105(6):1955–1959.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Li S, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8(1):13–23.
   PubMed Web of Science ®Google Scholar
• Soares R, Balogh G, Guo S, Gärtner F, Russo J, Schmitt F. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol. 2004;18(9):2333–2343.
   PubMedGoogle Scholar
• Sainson RC, Johnston DA, Chu HC, et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood. 2008;111(10):4997–5007.
   PubMed Web of Science ®Google Scholar
• Azizi E, Carr AJ, Plitas G, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293–1308.e1236.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416.
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012;65(2):159–163.
   PubMed Web of Science ®Google Scholar
• Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell. 2014;5(1):12–20.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–225.
   PubMed Web of Science ®Google Scholar
• Valković T, Lucin K, Krstulja M, Dobi-Babić R, Jonjić N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract. 1998;194(5):335–340.
   PubMed Web of Science ®Google Scholar
• Shen Q, Cohen B, Zheng W, et al. Notch Shapes the Innate Immunophenotype in Breast Cancer. Cancer Discov. 2017;7(11):1320–1335.
   PubMed Web of Science ®Google Scholar
• Lyu X. Innate and adaptive immune cells in tumor microenvironment. Gulf J Oncolog. 2021;1(35):77–81.
   PubMedGoogle Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339(6117):286–291.
   PubMed Web of Science ®Google Scholar
• Lin S, Sun L, Lyu X, et al. Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: a positive metabolic feedback loop. Oncotarget. 2017;8(66):110426–110443.
   PubMedGoogle Scholar
• Ahirwar DK, Charan M, Mishra S, et al. Slit2 inhibits breast cancer metastasis by activating M1-like phagocytic and antifibrotic macrophages. Cancer Res. 2021;81(20):5255–5267.
   PubMed Web of Science ®Google Scholar
• Zhao W, Hu X, Li W, et al. M2-like TAMs function reversal contributes to breast cancer eradication by combination dual immune checkpoint blockade and photothermal therapy. Small. 2021;17(13):e2007051.
   PubMed Web of Science ®Google Scholar
• Wang YC, He F, Feng F, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010;70(12):4840–4849.
   PubMed Web of Science ®Google Scholar
• Yin D, Wang W, Han W, Targeting Notch-activated FC. M1 macrophages attenuate lung tissue damage in a rat model of ventilator induced lung injury. Int J Mol Med. 2019;44(4):1388–1398.
   PubMed Web of Science ®Google Scholar
• Fukuda D, Aikawa E, Swirski FK, et al. Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci U S A. 2012;109(27):E1868–1877.
   PubMed Web of Science ®Google Scholar
• Pagie S, Gérard N, Charreau B. Notch signaling triggered via the ligand DLL4 impedes M2 macrophage differentiation and promotes their apoptosis. Cell Commun Signal. 2018;16(1):4.
   PubMed Web of Science ®Google Scholar
• Singla DK, Wang J, Singla R. Primary human monocytes differentiate into M2 macrophages and involve Notch-1 pathway. Can J Physiol Pharmacol. 2017;95(3):288–294.
   PubMed Web of Science ®Google Scholar
• Tao S, Chen Q, Lin C, Dong H. Linc00514 promotes breast cancer metastasis and M2 polarization of tumor-associated macrophages via Jagged1-mediated notch signaling pathway. J Exp Clin Cancer Res. 2020;39(1):191.
   PubMed Web of Science ®Google Scholar
• Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.
   PubMed Web of Science ®Google Scholar
• Rezaeifard S, Talei A, Shariat M, Erfani N. Tumor infiltrating NK cell (TINK) subsets and functional molecules in patients with breast cancer. Mol Immunol. 2021;136:161–167.
   PubMed Web of Science ®Google Scholar
• Chaves P, Zriwil A, Wittmann L, et al. Loss of canonical Notch signaling affects multiple steps in NK cell development in mice. J Immunol. 2018;201(11):3307–3319.
   PubMed Web of Science ®Google Scholar
• Beck RC, Padival M, Yeh D, Ralston J, Cooke KR, Lowe JB. The Notch ligands Jagged2, Delta1, and Delta4 induce differentiation and expansion of functional human NK cells from CD34+ cord blood hematopoietic progenitor cells. Biol Blood Marrow Transplant. 2009;15(9):1026–1037.
   PubMed Web of Science ®Google Scholar
• Nalin AP, Kowalski JJ, Sprague AC, et al. Notch regulates innate lymphoid cell plasticity during human NK cell development. J Immunol. 2020;205(10):2679–2693.
   PubMed Web of Science ®Google Scholar
• Wang K, Li L, Fu L, et al. Integrated bioinformatics analysis the function of RNA binding proteins (RBPs) and their prognostic value in breast cancer. Front Pharmacol. 2019;10:140.
   PubMed Web of Science ®Google Scholar
• Tao Z, Suo H, Zhang L, et al. MRPL13 is a prognostic cancer biomarker and correlates with immune infiltrates in breast cancer. Onco Targets Ther. 2020;13:12255–12268.
   PubMed Web of Science ®Google Scholar
• Manaster I, Gazit R, Goldman-Wohl D, et al. Notch activation enhances IFNgamma secretion by human peripheral blood and decidual NK cells. J Reprod Immunol. 2010;84(1):1–7.
   PubMed Web of Science ®Google Scholar
• Wenbo R, Jing H, Liancheng L. Progress in the study of the relationship between IFN-γ and the development of breast cancer. Shandong Med J. 2017;57(13):101–103.
   Google Scholar
• Brandstadter JD, Maillard I. Notch signalling in T cell homeostasis and differentiation. Open Biol. 2019;9(11):190187.
   PubMed Web of Science ®Google Scholar
• Van de Walle I, Dolens AC, Durinck K, et al. GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate. Nat Commun. 2016;7:11171. doi:10.1038/ncomms11171
   PubMed Web of Science ®Google Scholar
• Hozumi K, Negishi N, Tsuchiya I, et al. Notch signaling is necessary for GATA3 function in the initiation of T cell development. Eur J Immunol. 2008;38(4):977–985. doi:10.1002/eji.200737688
   PubMed Web of Science ®Google Scholar
• Li X, Cao Y, Jin F. HES1 expression and its correlation with prognosis in breast cancer. J Modern Oncol. 2018;26(06):0872–0875.
   Google Scholar
• De Obaldia ME, Bell JJ, Wang X, et al. T cell development requires constraint of the myeloid regulator C/EBP-α by the Notch target and transcriptional repressor Hes1. Nat Immunol. 2013;14(12):1277–1284. doi:10.1038/ni.2760
   PubMed Web of Science ®Google Scholar
• De Decker M, Lavaert M, Roels J, et al. HES1 and HES4 have non-redundant roles downstream of Notch during early human T-cell development. Haematologica. 2021;106(1):130–141. doi:10.3324/haematol.2019.226126
   PubMed Web of Science ®Google Scholar
• Rutz S, Mordmüller B, Sakano S, Scheffold A. Notch ligands Delta-like1, Delta-like4 and Jagged1 differentially regulate activation of peripheral T helper cells. Eur J Immunol. 2005;35(8):2443–2451. doi:10.1002/eji.200526294
   PubMed Web of Science ®Google Scholar
• Niu XL, Mao LQ, Ye L, Wang Y. Effects of IFN-γ and IL-4 on the growth and the estrogen receptor subtypes of breast cancer cell MCF-7. Chin J Cancer Prevention Treatment. 2011;18(20):1581–1584.
   Google Scholar
• Saleh ME, Gadalla R, Hassan H, et al. The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients. PLoS One. 2019;14(5):e0217550. doi:10.1371/journal.pone.0217550
   PubMed Web of Science ®Google Scholar
• Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109(8):2796–2801. doi:10.1073/pnas.1104303108
   PubMed Web of Science ®Google Scholar
• Mathieu M, Duval F, Daudelin JF, Labrecque N. The Notch signaling pathway controls short-lived effector CD8+ T cell differentiation but is dispensable for memory generation. J Immunol. 2015;194(12):5654–5662. doi:10.4049/jimmunol.1402837
   PubMed Web of Science ®Google Scholar
• De Sousa DM, Duval F, Daudelin JF, Boulet S, Labrecque N. The Notch signaling pathway controls CD8+ T cell differentiation independently of the classical effector HES1. PLoS One. 2019;14(4):e0215012. doi:10.1371/journal.pone.0215012
   PubMed Web of Science ®Google Scholar
• Oshi M, Asaoka M, Tokumaru Y, et al. CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci. 2020;21:18.
   Web of Science ®Google Scholar
• Elwakeel E, Weigert A. Breast cancer CAFs: spectrum of phenotypes and promising targeting avenues. Int J Mol Sci. 2021;22(21):21. doi:10.3390/ijms222111636
   Web of Science ®Google Scholar
• Shao H, Moller M, Cai L, et al. Converting melanoma-associated fibroblasts into a tumor-suppressive phenotype by increasing intracellular Notch1 pathway activity. PLoS One. 2021;16(3):e0248260. doi:10.1371/journal.pone.0248260
   PubMed Web of Science ®Google Scholar
• Du Y, Shao H, Moller M, Prokupets R, Tse YT, Liu ZJ. Intracellular Notch1 signaling in cancer-associated fibroblasts dictates the plasticity and stemness of melanoma stem/initiating cells. Stem Cells. 2019;37(7):865–875. doi:10.1002/stem.3013
   PubMed Web of Science ®Google Scholar
• Pupo M, Pisano A, Abonante S, Maggiolini M, Musti AM. GPER activates Notch signaling in breast cancer cells and cancer-associated fibroblasts (CAFs). Int J Biochem Cell Biol. 2014;46:56–67. doi:10.1016/j.biocel.2013.11.011
   PubMed Web of Science ®Google Scholar
• Pelon F, Bourachot B, Kieffer Y, et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat Commun. 2020;11(1):404. doi:10.1038/s41467-019-14134-w
   PubMed Web of Science ®Google Scholar
• Simon S, Labarriere NPD-1. Expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2017;7(1):e1364828. doi:10.1080/2162402X.2017.1364828
   PubMed Web of Science ®Google Scholar
• Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Structure. 2017;25(8):1163–1174. doi:10.1016/j.str.2017.06.011
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38):38. doi:10.1126/sciadv.abd2712
   Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
   PubMed Web of Science ®Google Scholar
• Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59.
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. doi:10.1186/s12943-018-0928-4
   PubMed Web of Science ®Google Scholar
• Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 2019;5(8):1205–1214. doi:10.1001/jamaoncol.2018.7147
   PubMed Web of Science ®Google Scholar
• Polk A, Svane I-M, Andersson M, Nielsen D. Checkpoint inhibitors in breast cancer – current status. Cancer Treat Rev. 2018;63:122–134. doi:10.1016/j.ctrv.2017.12.008
   PubMed Web of Science ®Google Scholar
• Vranic S, Cyprian FS, Gatalica Z, Palazzo J. PD-L1 status in breast cancer: current view and perspectives. Semin Cancer Biol. 2021;72:146–154. doi:10.1016/j.semcancer.2019.12.003
   PubMed Web of Science ®Google Scholar
• Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139(3):667–676. doi:10.1007/s10549-013-2581-3
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–370. doi:10.1158/2326-6066.CIR-13-0127
   PubMed Web of Science ®Google Scholar
• Huang W, Ran R, Shao B, Li H. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;178(1):17–33. doi:10.1007/s10549-019-05371-0
   PubMed Web of Science ®Google Scholar
• Chen W, Liu J, Ge F, et al. Long noncoding RNA HOTAIRM1 promotes immunosuppression in sepsis by inducing T cell exhaustion. J Immunol. 2022;208(3):618–632. doi:10.4049/jimmunol.2100709
   PubMed Web of Science ®Google Scholar
• Pan T, Liu Z, Yin J, Zhou T, Liu J, Qu H. Notch signaling pathway was involved in regulating programmed cell death 1 expression during sepsis-induced immunosuppression. Mediators Inflamm. 2015;2015:539841. doi:10.1155/2015/539841
   PubMed Web of Science ®Google Scholar
• Meng J, Jiang Y-Z, Zhao S, et al. Tumor-derived Jagged1 promotes cancer progression through immune evasion. Cell Rep. 2022;38(10):110492. doi:10.1016/j.celrep.2022.110492
   PubMed Web of Science ®Google Scholar
• Mansour FA, Al-Mazrou A, Al-Mohanna F, Al-Alwan M, Ghebeh H. PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis. Oncoimmunology. 2020;9(1):1729299. doi:10.1080/2162402X.2020.1729299
   PubMed Web of Science ®Google Scholar
• Savage PA, Klawon DEJ, Miller CH. Regulatory T cell development. Annu Rev Immunol. 2020;38(1):421–453. doi:10.1146/annurev-immunol-100219-020937
   PubMed Web of Science ®Google Scholar
• Yang Z, Qi Y, Lai N, et al. Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1. J Exp Clin Cancer Res. 2018;37(1):1. doi:10.1186/s13046-017-0664-4
   PubMed Web of Science ®Google Scholar
• Ohkura N, Hamaguchi M, Morikawa H, et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity. 2012;37(5):785–799. doi:10.1016/j.immuni.2012.09.010
   PubMed Web of Science ®Google Scholar
• Anastasi E, Campese AF, Bellavia D, et al. Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol. 2003;171(9):4504–4511. doi:10.4049/jimmunol.171.9.4504
   PubMed Web of Science ®Google Scholar
• Jiao W-E, Wei J-F, Kong Y-G, Xu Y, Tao -Z-Z, Chen S-M. Notch signaling promotes development of allergic rhinitis by suppressing Foxp3 expression and Treg cell differentiation. Int Arch Allergy Immunol. 2019;178(1):33–44. doi:10.1159/000493328
   PubMed Web of Science ®Google Scholar
• Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458–469. doi:10.1038/s41423-018-0004-4
   PubMed Web of Science ®Google Scholar
• He Z, Wu J, Zeng X, Bao H, Liu X. Role of the Notch ligands Jagged1 and Delta4 in Th17/Treg immune imbalance in a mouse model of chronic asthma. Exp Lung Res. 2021;47(6):289–299. doi:10.1080/01902148.2021.1933653
   PubMed Web of Science ®Google Scholar
• Wesseling-Rozendaal Y, van Doorn A, Willard-Gallo K, van de Stolpe A. Characterization of immunoactive and immunotolerant CD4+ T cells in breast cancer by measuring activity of signaling pathways that determine immune cell function. Cancers. 2022;14(3):490. doi:10.3390/cancers14030490
   PubMed Web of Science ®Google Scholar
• Kaushik B, Pal D, Saha S. Gamma secretase inhibitor: therapeutic target via NOTCH signaling in T cell acute lymphoblastic leukemia. Curr Drug Targets. 2021;22(15):1789–1798. doi:10.2174/1389450122666210203192752
   PubMed Web of Science ®Google Scholar
• Kumari M, Krishnamurthy PT, Pinduprolu S, Sola PDR-5. DR-5 and DLL-4 mAb functionalized SLNs of gamma-secretase inhibitors – an approach for TNBC treatment. Adv Pharm Bull. 2020;11(4):618–623. doi:10.34172/apb.2021.070
   PubMed Web of Science ®Google Scholar
• Chen X, Chen X, Zhou Z, et al. LY411575, a potent γ-secretase inhibitor, suppresses osteoclastogenesis in vitro and LPS-induced calvarial osteolysis in vivo. J Cell Physiol. 2019;234(11):20944–20956. doi:10.1002/jcp.28699
   PubMed Web of Science ®Google Scholar
• Means-Powell JA, Mayer IA, Ismail-Khan R, et al. A phase Ib dose escalation trial of RO4929097 (a γ-secretase inhibitor) in combination with exemestane in patients with ER +metastatic breast cancer (MBC). Clin Breast Cancer. 2022;22(2):103–114. doi:10.1016/j.clbc.2021.10.013
   PubMed Web of Science ®Google Scholar
• Massard C, Azaro A, Soria J-C, et al. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol. 2018;29(9):1911–1917. doi:10.1093/annonc/mdy244
   PubMed Web of Science ®Google Scholar
• Wang D, Xu J, Liu B, et al. IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer. Cell Death Differ. 2018;25(2):330–339. doi:10.1038/cdd.2017.162
   PubMed Web of Science ®Google Scholar
• Hossain F, Sorrentino C, Ucar DA, et al. Notch signaling regulates mitochondrial metabolism and NF-κB activity in triple-negative breast cancer cells via IKKα-dependent non-canonical pathways. Front Oncol. 2018;8:575.
   PubMed Web of Science ®Google Scholar
• Paroni G, Zanetti A, Barzago MM, et al. Retinoic acid sensitivity of triple-negative breast cancer cells characterized by constitutive activation of the Notch1 pathway: the role of Rarβ. Cancers. 2020;12:10.
   Web of Science ®Google Scholar
• Das A, Narayanam MK, Paul S, et al. A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling. J Biol Chem. 2019;294(17):6733–6750.
   PubMed Web of Science ®Google Scholar
• Smith DC, Eisenberg PD, Manikhas G, et al. A Phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014;20(24):6295–6303.
   PubMed Web of Science ®Google Scholar
• Silva G, Sales-Dias J, Casal D, et al. Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer. Cancers. 2021;13(16):48.
   Web of Science ®Google Scholar
• Yen WC, Fischer MM, Axelrod F, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015;21(9):2084–2095.
   PubMed Web of Science ®Google Scholar
• Jia H, Liu M, Wang X, et al. Cimigenoside functions as a novel γ-secretase inhibitor and inhibits the proliferation or metastasis of human breast cancer cells by γ-secretase/Notch axis. Pharmacol Res. 2021;169:105686.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu K, Han X, et al. Paeoniflorin influences breast cancer cell proliferation and invasion via inhibition of the Notch‑1 signaling pathway. Mol Med Rep. 2018;17(1):1321–1325.
   PubMed Web of Science ®Google Scholar
• Bawadood AS, Al-Abbasi FA, Anwar F, El-Halawany AM, Al-Abd AM. 6-Shogaol suppresses the growth of breast cancer cells by inducing apoptosis and suppressing autophagy via targeting notch signaling pathway. Biomed Pharmacother. 2020;128:110302.
   PubMed Web of Science ®Google Scholar
• Kushwaha PP, Singh AK, Shuaib M, et al. 3-O-(E)-p-Coumaroyl betulinic acid possess anticancer activity and inhibit Notch signaling pathway in breast cancer cells and mammosphere. Chem Biol Interact. 2020;328:109200.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang X, Li C, Guan H. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm J. 2017;25(4):638–643.
   PubMed Web of Science ®Google Scholar
• Dong J, Yang W, Han J, Cheng R, Li L. Effects of Notch signaling components from breast cancer cells treated in culture with resveratrol. Res Vet Sci. 2020;132:369–378.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy P, Dandawate P, Jensen RA, Anant S. Celastrol and triptolide suppress stemness in triple negative breast cancer: Notch as a therapeutic target for stem cells. Biomedicines. 2021;9(5):164.
   PubMed Web of Science ®Google Scholar
• Nasser F, Moussa N, Helmy MW, Haroun M. Dual targeting of Notch and Wnt/β-catenin pathways: potential approach in triple-negative breast cancer treatment. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(3):481–490.
   PubMed Web of Science ®Google Scholar
• Bai JW, Wei M, Li JW, Zhang GJ. Notch signaling pathway and endocrine resistance in breast cancer. Front Pharmacol. 2020;11:924.
   PubMed Web of Science ®Google Scholar
• Malik N, Yan H, Moshkovich N, et al. The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription. Nat Commun. 2019;10(1):2071.
   PubMed Web of Science ®Google Scholar
• Lin Q, Chen X, Meng F, et al. ASPH-Notch axis guided exosomal delivery of prometastatic secretome renders breast cancer multi-organ metastasis. Mol Cancer. 2019;18(1):156.
   PubMed Web of Science ®Google Scholar
• Jeong GY, Park MK, Choi HJ, et al. NSD3-induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progression. Cancer Res. 2021;81(1):77–90.
   PubMed Web of Science ®Google Scholar
• Liu X, Xian Y, Xu H, et al. The associations between Deltex1 and clinical characteristics of breast cancer. Gland Surg. 2021;10(11):3116–3127.
   PubMed Web of Science ®Google Scholar
• Jaiswal A, Murakami K, Elia A, et al. Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2021;118(38):45.
   Web of Science ®Google Scholar
• Zhang HS, Zhang ZG, Du GY, et al. Nrf2 promotes breast cancer cell migration via up-regulation of G6PD/HIF-1α/Notch1 axis. J Cell Mol Med. 2019;23(5):3451–3463.
   PubMed Web of Science ®Google Scholar
• Gao P, Peng T, Lin S, et al. Key role of MCUR1 in malignant progression of breast cancer. Onco Targets Ther. 2021;14:4163–4175.
   PubMed Web of Science ®Google Scholar
• Fournier P, Viallard C, Dejda A, Sapieha P, Larrivée B, Royal I. The protein tyrosine phosphatase PTPRJ/DEP-1 contributes to the regulation of the Notch-signaling pathway and sprouting angiogenesis. Angiogenesis. 2020;23(2):145–157.
   PubMed Web of Science ®Google Scholar